Journal article
AIT-082, a novel purine derivative with neuroregenerative properties
Abstract
Preclinical and clinical evidence support the effectiveness of neurotrophins in Alzheimer's disease (AD) and neurodegenerative diseases. Delivery of neurotrophins to target sites in the brain remains a major obstacle for their use in humans. Development of orally active agents that mimic the effects of nerve growth factor and other neurotrophins provides a promising alternative therapeutic strategy. AIT-082, a purine analogue, has been shown to …
Authors
Glasky AJ; Glasky MS; Ritzmann RF; Rathbone MP
Journal
Expert Opinion on Investigational Drugs, Vol. 6, No. 10, pp. 1413–1417
Publisher
Taylor & Francis
Publication Date
October 1997
DOI
10.1517/13543784.6.10.1413
ISSN
1354-3784